Bui K C, Walther F J, David-Cu R, Garg M, Warburton D
Division of Neonatology and Pediatric Pulmonology Children's Hospital of Los Angles, University of Southern California School of Medicine.
J Pediatr. 1992 Aug;121(2):271-4. doi: 10.1016/s0022-3476(05)81202-8.
To test the hypothesis that infants with severe respiratory failure and the need for extracorporeal membrane oxygenation (ECMO) are surfactant deficient, we measured the amount of surfactant phospholipids, disaturated phosphatidylcholine, surfactant protein A, and protein in tracheal aspirates from 22 infants, who received ECMO therapy for respiratory failure with meconium aspiration syndrome (n = 18) or pneumonia (n = 4). Tracheal suction material was obtained in a standardized way every 4 hours during the period of ECMO treatment and pooled for 24-hour periods. During ECMO, mean total phospholipid, disaturated phosphatidylcholine, and surfactant protein A values in tracheal aspirates increased and protein values decreased significantly, predominantly during the 72-hour period before infants were weaned from ECMO. Of the 22 infants, 14 had an increase in tracheal aspirate phospholipid values of more than 200% and were found to need a shorter period of ECMO support (p less than 0.005) and post-ECMO ventilatory support (p less than 0.025) than did the eight infants with stationary or only moderate increases in tracheal aspirate phospholipid values, three of whom had pneumonia. We conclude that infants with respiratory failure who require ECMO treatment often have surfactant deficiency. We speculate that surfactant treatment might decrease the need for or the duration of ECMO support.
为验证患有严重呼吸衰竭且需要体外膜肺氧合(ECMO)的婴儿存在表面活性剂缺乏这一假说,我们测量了22名接受ECMO治疗的婴儿气管吸出物中表面活性剂磷脂、二饱和磷脂酰胆碱、表面活性剂蛋白A和蛋白质的含量,这些婴儿因胎粪吸入综合征(n = 18)或肺炎(n = 4)导致呼吸衰竭而接受ECMO治疗。在ECMO治疗期间,每4小时以标准化方式获取气管吸出物,并将其合并为24小时的样本。在ECMO治疗期间,气管吸出物中的平均总磷脂、二饱和磷脂酰胆碱和表面活性剂蛋白A值增加,而蛋白质值显著下降,主要发生在婴儿脱离ECMO前的72小时内。在这22名婴儿中,14名婴儿气管吸出物磷脂值增加超过200%,与8名气管吸出物磷脂值稳定或仅适度增加的婴儿相比,发现他们需要的ECMO支持时间更短(p小于0.005),且ECMO后通气支持时间更短(p小于0.025),这8名婴儿中有3名患有肺炎。我们得出结论,需要ECMO治疗的呼吸衰竭婴儿通常存在表面活性剂缺乏。我们推测表面活性剂治疗可能会减少对ECMO支持的需求或缩短其持续时间。